Motexafin gadolinium hydrate (BioDeep_00001030181)
代谢物信息卡片
Motexafin gadolinium hydrate
化学式: C52H76GdN5O15- (1168.4578756)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCC1=C(C2=CC3=NC(=CN=C4C=C(C(=CC4=NC=C5C(=C(C(=N5)C=C1[N-]2)CCCO)C)OCCOCCOCCOC)OCCOCCOCCOC)C(=C3CCCO)C)CC.CC(=O)O.CC(=O)O.O.[Gd]
InChI: InChI=1S/C48H66N5O10.2C2H4O2.Gd.H2O/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40
描述信息
D011838 - Radiation-Sensitizing Agents > D017319 - Photosensitizing Agents
D000970 - Antineoplastic Agents
D003879 - Dermatologic Agents
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Stephen C Kanick, Julie L Eiseman, Robert S Parker. Pharmacokinetic modeling of motexafin gadolinium disposition in mouse tissues using optical pharmacokinetic system measurements.
Photodiagnosis and photodynamic therapy.
2008 Dec; 5(4):276-84. doi:
10.1016/j.pdpdt.2008.11.005. [PMID: 19356671] - Robert J Amato, Jaroslaw Jac, Joan Hernandez-McClain. Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results.
Clinical genitourinary cancer.
2008 Sep; 6(2):73-8. doi:
10.3816/cgc.2008.n.011. [PMID: 18824428] - G W Boswell, D R Miles, P A Thiemann, M Mesfin. Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin) in CD1 mice following intravenous and intraperitoneal injection.
Investigational new drugs.
2006 Jul; 24(4):281-9. doi:
10.1007/s10637-006-5383-1. [PMID: 16538526] - Dale R Miles, Mimi Mesfin, Tarak D Mody, Mark Stiles, Jean Lee, John Fiene, Bernie Denis, Garry W Boswell. Validation and use of three complementary analytical methods (LC-FLS, LC-MS/MS and ICP-MS) to evaluate the pharmacokinetics, biodistribution and stability of motexafin gadolinium in plasma and tissues.
Analytical and bioanalytical chemistry.
2006 May; 385(2):345-56. doi:
10.1007/s00216-006-0414-5. [PMID: 16609840] - Lucius S Doh, Robert Amato, Arnold C Paulino, Bin S Teh. Radiation therapy in the management of brain metastases from renal cell carcinoma.
Oncology (Williston Park, N.Y.).
2006 May; 20(6):603-13; discussion 613, 616, 619. doi:
NULL. [PMID: 16773845] - Ramesh K Ramanathan, Marwan Fakih, Sridhar Mani, Melvin Deutsch, Raymond P Perez, Mark A Ritter, Julie L Eiseman, S Percy Ivy, Donald L Trump, Chandra P Belani, Robert A Parise, Douglas M Potter, Merrill J Egorin. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
Cancer chemotherapy and pharmacology.
2006 Apr; 57(4):465-74. doi:
10.1007/s00280-005-0071-y. [PMID: 16133531] - Dale R Miles, Jennifer A Smith, See-Chun Phan, Sammy J Hutcheson, Markus F Renschler, Judith M Ford, Garry W Boswell. Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme.
Journal of clinical pharmacology.
2005 Mar; 45(3):299-312. doi:
10.1177/0091270004271946. [PMID: 15703365] - Patrick Rodrigus. Motexafin gadolinium: a possible new radiosensitiser.
Expert opinion on investigational drugs.
2003 Jul; 12(7):1205-10. doi:
10.1517/13543784.12.7.1205. [PMID: 12831354] - Sara Rockwell, Erling T Donnelly, Yanfeng Liu, Li-Qun Tang. Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro.
International journal of radiation oncology, biology, physics.
2002 Oct; 54(2):536-41. doi:
10.1016/s0360-3016(02)02962-0. [PMID: 12243833] - R A Miller, K W Woodburn, Q Fan, I Lee, D Miles, G Duran, B Sikic, D Magda. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2001 Oct; 7(10):3215-21. doi:
NULL. [PMID: 11595717] - K W Woodburn. Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy.
The Journal of pharmacology and experimental therapeutics.
2001 Jun; 297(3):888-94. doi:
NULL. [PMID: 11356908] - G M Griffin, T Zhu, M Solonenko, F Del Piero, A Kapakin, T M Busch, A Yodh, G Polin, T Bauer, D Fraker, S M Hahn. Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2001 Feb; 7(2):374-81. doi:
NULL. [PMID: 11234893] - R A Parise, D R Miles, M J Egorin. Sensitive high-performance liquid chromatographic assay for motexafin gadolinium and motexafin lutetium in human plasma.
Journal of chromatography. B, Biomedical sciences and applications.
2000 Dec; 749(2):145-52. doi:
10.1016/s0378-4347(00)00390-x. [PMID: 11145051] - D I Rosenthal, C R Becerra, R D Toto, D P Carbone, E P Frenkel. Reversible renal toxicity resulting from high single doses of the new radiosensitizer gadolinium texaphyrin.
American journal of clinical oncology.
2000 Dec; 23(6):593-8. doi:
10.1097/00000421-200012000-00013. [PMID: 11202804] - M S Blumenkranz, K W Woodburn, F Qing, S Verdooner, D Kessel, R Miller. Lutetium texaphyrin (Lu-Tex): a potential new agent for ocular fundus angiography and photodynamic therapy.
American journal of ophthalmology.
2000 Mar; 129(3):353-62. doi:
10.1016/s0002-9394(99)00462-6. [PMID: 10704552] - R A Miller, K Woodburn, Q Fan, M F Renschler, J L Sessler, J A Koutcher. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer.
International journal of radiation oncology, biology, physics.
1999 Nov; 45(4):981-9. doi:
10.1016/s0360-3016(99)00274-6. [PMID: 10571206] - D I Rosenthal, P Nurenberg, C R Becerra, E P Frenkel, D P Carbone, B L Lum, R Miller, J Engel, S Young, D Miles, M F Renschler. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.
Clinical cancer research : an official journal of the American Association for Cancer Research.
1999 Apr; 5(4):739-45. doi:
NULL. [PMID: 10213207] - K W Woodburn, Q Fan, D Kessel, Y Luo, S W Young. Photodynamic therapy of B16F10 murine melanoma with lutetium texaphyrin.
The Journal of investigative dermatology.
1998 May; 110(5):746-51. doi:
10.1046/j.1523-1747.1998.00182.x. [PMID: 9579539] - C F Geraldes, A D Sherry, P Vallet, F Maton, R N Muller, T D Mody, G Hemmi, J L Sessler. Nuclear magnetic relaxation dispersion studies of water-soluble gadolinium(III)-texaphyrin complexes.
Journal of magnetic resonance imaging : JMRI.
1995 Nov; 5(6):725-9. doi:
10.1002/jmri.1880050618. [PMID: 8748493] - S W Young, M K Sidhu, F Qing, H H Muller, M Neuder, G Zanassi, T D Mody, G Hemmi, W Dow, J D Mutch. Preclinical evaluation of gadolinium (III) texaphyrin complex. A new paramagnetic contrast agent for magnetic resonance imaging.
Investigative radiology.
1994 Mar; 29(3):330-8. doi:
10.1097/00004424-199403000-00013. [PMID: 8175308]